Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients With Type 2 Diabetes and CKD

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 210 participants.

Also called NCT06820567

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 210 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06820567
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06820567. Randomized; quadruple masking; primary purpose treatment. Start 2025-03-01 (anticipated); primary completion 2026-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients With Type 2 Diabetes and CKD
Condition
Chronic Kidney Diseases
Condition
Diabetes Type 2
Intervention (Drug)
Dapagliflozin (DAPA)
Intervention (Drug)
Placebo
Lead sponsor
Assiut University (class: other)

Record details

Record id
cardio:ct-nct06820567
Content hash
455bfee524015d0b00dbeb32285823dc926836a61189b3dae506312c81f5fda3